<DOC>
	<DOCNO>NCT01272206</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety pharmacokinetics ( rate body eliminate trial drug ) NNC 0128-0000-2011 compare NNC 0128-0000-2021 give first time healthy human subject .</brief_summary>
	<brief_title>Investigating Safety Pharmacokinetics NNC 0128-0000-2011 Compared NNC 0128-0000-2021 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Body weight 50.0 100.0 kg , inclusive Body mass index ( BMI ) 18.0 28.0 kg/m2 , inclusive Known suspect hypersensitivity trial product relate product , activate recombinant factor VII Any clinical sign know history atherosclerosis thromboembolic event Renal dysfunction A subject consider high risk thromboembolic event Overt bleeding , include gastrointestinal tract Hepatitis B C infection Human immunodeficiency virus ( HIV ) infection Positive test drug abuse alcohol well history alcohol drug abuse within past 12 month Smoking within 3 month prior trial start Unable abstain alcohol consumption visit trial product administration , visit 2 ( 028 day screen ) visit 3 ( 24 week visit 2 ) Habitual excessive consumption methylxanthinecontaining beverage food ( coffee , tea , soft drink cola , chocolate ) judge investigator ( trial physician ) Excessive consumption diet deviate normal diet Blood donation within last three month prior screen The receipt investigational product within 30 day trial product administration Participation trial investigate procoagulant within last six month prior screen Strenuous exercise within four day prior trial start Suffers life threaten disease Males sexually active surgically sterilise , whose partner use adequate contraceptive method ( adequate contraceptive measure require local law practise ) . Subjects increase cardiovascular risk , include strong family history cardiovascular disease Subjects high fast cholesterol trial start</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>